H101 Plus TACE for r/m HNSCC

计划入组 20 人 · 首次发布于 2026 年 2 月 10 日

Ribociclib and Spartalizumab in R/M HNSCC

计划入组 13 人 · 首次发布于 2019 年 12 月 30 日

Trilaciclib Combined With Immunochemotherapy for R/M HNSCC

计划入组 32 人 · 首次发布于 2026 年 7 月 1 日

R-21

M-5291

M-121101

R&R, Inc.

United States

BATEMAN, TIMOTHY M. M. MD

United States

MICHAEL WAGNER

Australia

Pyxis Oncology's MICVO Posts 36% Confirmed ORR and 79% 12-Month OS Probability in 2L+ R/M Head and Neck Cancer

Akeso's Phase 3 Trial Begins for Ivonescimab and Ligufalimab Combination in Head and Neck Cancer

FDA Grants Fast Track Status to Pyxis Oncology's PYX-201 for Advanced Head and Neck Cancer